Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 6/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2253345 | 0.94 | CA12 (0.55) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL6932897 | 0.92 | KDM4E (0.50) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3571825 | 0.91 | KDM4E (0.52) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3560451 | 0.91 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2299912 | 0.90 | PTGER4 (0.47) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3560912 | 0.90 | ADORA3 (0.45) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3569001 | 0.89 | PTGER4 (0.42) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2300382 | 0.89 | PTGER4 (0.46) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2300372 | 0.89 | PTGER4 (0.46) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3566659 | 0.88 | KDM4E (0.45) | KDM4EALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1886993-B1 | BENZO[F]ISOINDOLE DERIVATIVES WITH AFFINITY TO THE EP4 RECEPTOR | GLAXO GROUP LTD (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-7732622-B2 | Naphthalene derivatives | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20080234358-A1 | E-series of prostaglandin (EP) receptors; [[4-(4,9-dipropoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl) phenyl]acetic acid | CONGREVE MILES STUART | 2008-09-25 | — | — | US | disclosed |
| EP-1886993-A1 | BENZO[F]ISOINDOLE DERIVATIVES WITH AFFINITY TO THE EP4 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-02-13 | — | — | EP | disclosed |
| EP-1351934-B1 | NAPHTHALENE DERIVATIVES WHICH BIND TO THE EP4 RECEPTOR | GLAXO GROUP LTD (GB) | 2007-08-29 | — | — | EP | disclosed |
| EP-1368312-B1 | BENZO[F]ISOINDOLE DERIVATIVES WITH AFFINITY TO THE EP4 RECEPTOR | GLAXO GROUP LTD (GB) | 2007-06-27 | — | — | EP | disclosed |
| US-20070088068-A1 | Benzo[F]Isoindole Derivatives With Affinity To The EP4 Receptor | CONGREVE MILES S | 2007-04-19 | — | — | US | disclosed |
| US-7173047-B2 | Benzo (f) insoindol derivatives and their use as ep4 receptor ligands | GLAXO GROUP LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| US-7166631-B2 | Benzo[f]isoindole derivatives with affinity to the EP4 receptor | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| EP-1442744-B1 | EP4 receptor ligand and use against neuropathic pain, colon cancer, HIV and migrane | GLAXO GROUP LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20050080257-A1 | Benzo'fisoindole derivatives with affinity to the ep4 receptor | GLAXO GROUP LIMITED (GB) | 2005-04-14 | — | — | US | disclosed |
| US-6861441-B1 | Use of EP4 receptor ligands in the treatment of neuropathic pain and colon cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1442744-A2 | Use of EP4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer | GLAXO GROUP LIMITED (GB) | 2004-08-04 | — | — | EP | disclosed |
| EP-1202730-B1 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF NEUROPATHIC PAIN | GLAXO GROUP LTD (GB) | 2004-08-04 | — | — | EP | disclosed |
| US-20040102508-A1 | Naphathalene derivatives which bind to the ep4 receptor | SMITHKLINE BEECHAM CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-20040087624-A1 | Benzo (f) insoindol derivatives and their use as ep4 receptor ligands | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | US | disclosed |
| EP-1368312-A1 | BENZO'F!ISOINDOLE DERIVATIVES WITH AFFINITY TO THE EP4 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002064564-A1 | BENZO'F!ISOINDOLE DERIVATIVES WITH AFFINITY TO THE EP4 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2002-08-22 | — | — | WO | disclosed |
| EP-1202730-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF NEUROPATHIC PAIN AND COLON CANCER | GLAXO GROUP LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010426-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF NEUROPATHIC PAIN AND COLON CANCER | GLAXO GROUP LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102508-A1 | Naphathalene derivatives which bind to the ep4 receptor | PTGER4, PTGER1, PTGER3 | KDM4E 3281/4885ALDH1A1 1587/4885MAPT 3731/4885 |
| US-20050080257-A1 | Benzo'fisoindole derivatives with affinity to the ep4 receptor | PTGER4, PTGER1, PTGER3 | KDM4E 835/4885ALDH1A1 1672/4885MAPT 4190/4885 |
| US-20070088068-A1 | Benzo[F]Isoindole Derivatives With Affinity To The EP4 Receptor | PTGER4, PTGER1, GPR4 | KDM4E 1551/4885ALDH1A1 1118/4885MAPT 4449/4885 |
| US-20080234358-A1 | E-series of prostaglandin (EP) receptors; [[4-(4,9-dipropoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl) phenyl]acetic acid | PTGER3, OPRL1, PTGER1 | KDM4E 4614/4885ALDH1A1 565/4885MAPT 4831/4885 |
| US-20040087624-A1 | Benzo (f) insoindol derivatives and their use as ep4 receptor ligands | PTGER4, PTGER1, OPRL1 | KDM4E 2825/4885ALDH1A1 1220/4885MAPT 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.